*J. Clin. Med.* **2020**, *9*, 1362

clinical trials with increasing insurance support, the treatment of lung cancer has entered a new era. Several trials in advanced NSCLC have reported improved survival with anti-PD-1/PD-L1 antibodies treatment, both when used alone and in combination with chemotherapy (Table 1). This article thus elaborates on the immune checkpoint inhibitors used for treating lung cancer.


**Table 1.** Trials of ICIs for advanced stage NSCLC.
